# Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

> **NCT03749317** · PHASE2 · COMPLETED · sponsor: **IVIEW Therapeutics Inc.** · enrollment: 135 (actual)

## Conditions studied

- Adenoviral Conjunctivitis

## Interventions

- **DRUG:** IVIEW-1201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03749317
- **Lead sponsor:** IVIEW Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-20
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03749317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03749317, "Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03749317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*